13472-85-0

Basic information

• Product Name: 5-Bromo-2-methoxypyridine
• Synonyms: 2-METHOXY-5-BROMOPYRIDINE 5-BROMO-2-METHOXY-PYRIDINE;5-Bromo-2-methoxypyridine 95%;5-Bromo-2-methoxypyridine ,98%;5-Bromo-2-methoxypyridine,97%;(E)-N-(pyridin-3-ylmethylene)methanamine;5-Bromo-2-methoxypyr;5-BroMo-2-Methoxypyridine, 97% 5ML;2-Methoxy -5-pyridyl broMide
• CAS NO: 13472-85-0
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.02
• EINECS: -0
• Product Categories: Pyridine Series;Pyridines, Pyrimidines, Purines and Pteredines;Pyridines derivates;Alkoxy;Organohalides;Anisoles, Alkyloxy Compounds & Phenylacetates;Bromine Compounds;Miscellaneous Compounds;Bromopyridines;Halopyridines;Boronic Acid;C6Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Brominated heterocyclic series;alkyl bromide;compounds of pyridine;blocks;Bromides;Pyridines;Pyridine;pyridine derivative
• Mol File: 13472-85-0.mol

Chemical Properties

• Melting Point: 80°C (12 mmHg)
• Boiling Point: 80 °C12 mm Hg(lit.)
• Flash Point: 205 °F
• Appearance: Clear colorless to slightly yellow/Liquid
• Density: 1.453 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.545mmHg at 25°C
• Refractive Index: n20/D 1.555(lit.)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 1.04±0.10(Predicted)
• BRN: 115150
• CAS DataBase Reference: 5-Bromo-2-methoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-methoxypyridine(13472-85-0)
• EPA Substance Registry System: 5-Bromo-2-methoxypyridine(13472-85-0)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-20/21/22
• Safety Statements: 26-36-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 13472-85-0(Hazardous Substances Data)

Usage

Uses

1. Pharmaceutical Industry:
5-Bromo-2-methoxypyridine is used as a building block for the synthesis of various pharmaceutical compounds. Specifically, it is utilized in the creation of the β-alanine moiety of an αvβ3 antagonist, which plays a crucial role in inhibiting certain biological processes. Additionally, it is employed in the synthesis of a potent and selective somatostatin sst3 receptor antagonist, which can be beneficial in treating various medical conditions related to the somatostatin system.
2. Central Nervous System Applications:
In the field of neuroscience, 5-Bromo-2-methoxypyridine is used as a ligand for the central nicotinic acetylcholine receptor. This application is significant as it can help in understanding the role of these receptors in cognitive functions and potentially contribute to the development of treatments for neurological disorders.
3. Antiviral Applications:
5-Bromo-2-methoxypyridine is also used in a novel synthetic approach to develop anti-HIV active integrase inhibitors. These inhibitors are essential in the fight against HIV as they can help prevent the integration of the virus into the host's DNA, thereby limiting its replication and spread.

InChI:InChI=1/C6H6BrNO/c1-9-6-3-2-5(7)4-8-6/h2-4H,1H3

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 1072-97-5 5-bromo-2-pyridylamine 
• 149-73-5 trimethyl orthoformate 
• 223463-13-6 2-iodo-5-bromopyridine 
• 124-41-4 sodium methylate 
• 53939-30-3 5-bromo-2-chloropyridine 
• 67-56-1 methanol 
• 1628-89-3 2-methoxypyridine 
• 39856-50-3 5-bromo2-nitropyridine 
• 34851-41-7 tetrabutyl ammonium methoxide 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 13466-38-1 5-bromopyridin-2(1H)-one 
• 74-88-4 methyl iodide 

Downstream Products

• 51834-97-0 6-methoxypyridine-3-ol 
• 32401-36-8 (6-methoxypyridin-3-yl)(phenyl)methanone 
• 164014-93-1 2-methoxy-5-(1,1,1-tributylstannyl)pyridine 
• 1046143-58-1 5-(2-chlorophenoxy)-2-methoxypyridine 
• 1046143-59-2 5-(2,4-dichlorophenoxy)-2-methoxypyridine 
• 1231691-24-9 C₁₉H₁₈N₆O₃ 
• 893736-64-6 2-methoxy-5-(p-tolyl)pyridine 
• 105189-42-2 4,4'-dimethoxy-3,3'-bis<(2-methoxypyrid-5-yl)methyl>diphenyliodonium perchlorate 
• 105189-64-8 L-3,5-dinitro-4-(4'-methoxy-3'-(6-methoxy-3-pyridylmethyl)-phenylthio)-N-trifluoroacetyl phenylalanine ethyl ester 
• 105189-65-9 L-3,5-diiodo-4-(4'-methoxy-3'-(6-methoxy-3-pyridylmethyl)-phenylthio)-N-trifluoracetyl phenylalanine ethyl ester 
• 105189-68-2 L-3,5-dibromo-4-(4'-methoxy-3'-(6-methoxy-3-pyridylmethyl)phenylthio)-N-trifluoroacetyl phenylalanine ethyl ester 
• 105189-46-6 3,5-dibromo-3'-<(2-methoxypyrid-5-yl)methyl>-O-methyl-N-(trifluoroacetyl)-L-thyronine methyl ester 
• 105189-58-0 L-3,5-dichloro-3'-(6-methoxy-3-pyridylmethyl)-O-methyl-N-trifluoroacetyl thyronine methyl ester 
• 105189-74-0 N-acetyl-3,5-dimethyl-O-methyl-3'-<(2-methoxypyrid-5-yl)methyl>-DL-thyronine 

Relevant articles and documents

Preparation method of ortho-alkoxy substituted pyridine compound

The invention provides a preparation method of an ortho-alkoxy substituted pyridine compound, the preparation method comprises the following step: reacting an ortho-amino substituted pyridine compound with an ortho-formate compound in the presence of a nitrite compound to generate the ortho-alkoxy substituted pyridine compound. The method has the advantages of high efficiency, low cost, environmental protection and the like.

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.

Preparation method of 2,5-dimethoxy pyridine

The invention discloses a preparation method of 2,5-dimethoxy pyridine, and belongs to the technical field of medicine synthesis. The method comprises the following steps that 1, under the existence of an alcohol solvent, a compound shown as a formula A and sodium methoxide take contact reaction to form a compound shown as a formula B; 2, under the existence of metal catalysts, the compound shownas a formula B in the first step reacts to obtain 2,5-dimethoxy pyridine; aftertreatment and purification are performed to obtain the product. The method has the advantages that the route is short; the steps are few; expensive palladium catalysts and boracic acid catalysts are not used; the equipment cost is reduced; the use of flammable and explosive lithium reagents and peroxide is avoided; thereaction conditions are mild; the aftertreatment operation is simple and convenient; the total yield and the purity are improved; the product quality can be easily controlled; the industrial amplification prospects are good.

COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY

The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a BCL-2 inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and a BCL-2 inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a BCL-2 inhibitor and a pharmaceutically acceptable carrier or excipient.

Novel synthesis method for ortho-alkane superseded pyridine

The invention relates to a novel synthesis method for ortho-alkane superseded pyridine. According to the method, ortho halogenated pyridine serves as raw materials, the ortho halogenated pyridine and corresponding alcohol react to obtain the ortho-alkane superseded pyridine under the action of sodium hydroxide. The reaction has universality for the ortho halogenated pyridine, and the method is simple and practical. Influence of consumption of the sodium hydroxide on mono-substitution and di-substitution in the reaction is inspected, alkoxy mono-substitution products and alkoxy di-substitution production are acquired, and a novel simply-operated, economical and favorable process for synthesis ortho-alkane superseded pyridine is provided.

Reversible Folding of a β-Hairpin Peptide by a Metal-Chelating Amino Acid

5-(1-Hydroxy-pyridin-2(1H)-onyl)-l-alanine (Hop) is a N-hydroxy-1,2-pyridone functionalized α-amino acid with the desired metal-chelating properties of DOPA (3,4-dihydroxy phenylalanine) but without its unwanted redox activity. The Fmoc-protected amino acid Fmoc-l-Hop(tBu)-OH (11) was synthesized from glycine phosphonate followed by enzymatic hydrolysis of the methyl ester yielding the Hop l-isomer in 96 % ee. The amino acid 11 is used in automated peptide synthesis for the assembly of a 14mer β-hairpin peptide with the sequence [dsb1, 14]H-CHXETGKHGHKLVC-OH (X=W, l-Hop). While the 10 π electron containing indole side chain of l-Trp in peptide 14 completes the formation of a hydrophobic cluster and results in 90 % folding, the folded fraction is significantly decreased to approximately 30 % for the 6 π electron l-Hop side chain in peptide 16. Metal chelation of Ga3+ reconstitutes the folding of 16 to above 60 % due to the formation of the Ga(16)3 trimer. The chelation process of 16 is monitored by NMR spectroscopy and the subsequent release of Ga3+ by a competitive metal chelator exemplifies the reversible oligomerization of peptide epitopes by metal chelation, bearing the opportunity to synthesize protein-sized aggregates on the basis of reversible chemistry in water.

COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE

This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administrat

Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

The invention provides a compound of Formula I, Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in

Arylpyridinone ITK inhibitors for treating inflammation and cancer

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein Ar, R2, R4, R5, n and X are as defined in